Strong sales and income growth for Boehringer Ingelheim in 2016

5 April 2017

In 2016, German family-owned pharma major Boehringer Ingelheim generated net sales of around 15.9 billion euros ($16.9 billion), representing an increase of 7.3% in currency-adjusted terms (+7.1% in euro terms). Since operating income improved by 27% to around 2.9 billion euros, the return on net sales came to 18.1%, the company noted.

Overall, net sales of prescription medicines – Boehringer Ingelheim’s largest business – increased by 7.4% in currency-adjusted terms to around 12 billion euros (+7.5% in euro terms). With net sales of just under 3 billion euros, down 14.9% year-on-year, the respiratory drug Spiriva (tiotropium) remains the best-selling medicine for the company.

The oral anticoagulant Pradaxa (dabigatran) saw sales increase 6.8% to 1.4 billion euros. Type 2 diabetes agent Trajenta/Jentadueto (linagliptin) generated sales of 1.1 billion euros, a rise of 23.1% while ofev (nintedanib), used to treat idiopathic pulmonary fibrosis (IPF), posted sales of 600 million euros, leaping 106.4%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK